SereNeuro closes pre-seed for non-opioid pain pipeline. The biology behind SereNeuro Therapeutics began as a research model rather than a therapy. Johns Hopkins scientists created human pain-sensing neurons from induced pluripotent stem cells to study peripheral pain, placed the cells into a joint model, and observed an unexpected therapeutic effect. That result became SN101. SereNeuro Therapeutics has now closed an oversubscribed pre-seed financing to move SN101 toward the manufacturing and preclinical work required for an Investigational New Drug application. The amount and valuation were not disclosed. Two Maryland venture firms and a physician investor participated, but the company did not identify them. The financing is a bet on an unusual biological inversion. Pain medicine often tries to block or quiet nociceptors, the sensory neurons that detect damaging stimuli. SereNeuro is developing a treatment that adds mature nociceptors to an arthritic joint and asks those cells to absorb inflammatory pain factors without relaying the signals to the brain. The company also says the cells release regenerative factors that may help preserve cartilage, though those claims remain preclinical. From research tool to therapy candidate. SereNeuro's scientific co-founders Xinzhong Dong, Gabsang Lee, and Zhuolun "Poppy" Wang originally built a human iPSC-derived model of peripheral pain-sensing neurons to discover non-opioid pain targets. Dong said the model was never intended to become a drug. When the team tested the cells in a joint-pain model, the unexpected effect changed the direction of the work. SN101 is now described as an off-the-shelf therapy made from purified human nociceptors. SereNeuro says the cells carry the channel identity of native dorsal root ganglion neurons, including Nav1.7, Nav1.8, and Nav1.9. Delivered by injection into an affected joint, the candidate is designed to sequester inflammatory pain factors while preserving joint structure. The company presented preclinical SN101 findings at an International Society for Stem Cell Research symposium in December 2025. SereNeuro reported pain relief and reduced cartilage degeneration in preclinical models. Independent Technical.ly reporting says the company has tested the therapy in primates and collected data from joint-fluid samples from people with osteoarthritis. Those signals support continued development, but they are not evidence of safety or efficacy in patients. What the pre-seed round funds. The round moves SN101 deeper into IND-enabling work. Daniel Saragnese, SereNeuro's CEO and co-founder, said the capital and the company's non-dilutive funding will support manufacturing and preclinical studies. Technical.ly reported that SereNeuro was preparing for a November 2026 meeting with the FDA and had already used some financing to add staff. The current leadership team includes Laura Richman as CSO, Oliver Kraemer as CTO, and Tea Soon Park as senior principal scientist for cell therapy. Richman's appointment adds development experience as the company prepares to translate a laboratory observation into a reproducible product, a regulatory package, and eventually a clinical study. For an iPSC-derived therapy, the manufacturing question is part of the medicine because cell identity, purity, maturity, consistency, and delivery all shape the risk profile. The investment also reflects Maryland's effort to finance local biotechnology. SereNeuro said qualifying investors used the state's Biotechnology Investment Incentive Tax Credit at the enhanced refundable rate available to companies inside a federal Opportunity Zone. Its East Baltimore site sits inside that geography and near Johns Hopkins research and commercialization infrastructure. SN102 adds a separate non-opioid pain program. SereNeuro is using the round to support SN102 as well, though the second program follows a different modality and funding path. SN102 is an in vivo gene-therapy program for trigeminal neuralgia and other neuropathic pain. The company says the approach is designed to reduce hyperactive pain signaling while preserving ordinary sensation and motor function. In September 2026, SereNeuro received a $318,000 Phase I Small Business Innovation Research award from the National Institute of Dental and Craniofacial Research. The award, issued under the NIH Helping to End Addiction Long-term Initiative, supports SN102. That grant is separate from the pre-seed round and should not be combined with the undisclosed financing amount. The two programs show how SereNeuro is approaching pain through different biological systems. SN101 places new cells at the site of chronic joint pain, while SN102 aims to alter the excitability of existing sensory neurons. Both remain preclinical, and each will face its own manufacturing, delivery, safety, and regulatory questions. Why the evidence boundary matters. Chronic osteoarthritis pain is not a single pathway waiting for one switch. Inflammation, sensitized peripheral nerves, changes in joint tissue, and central pain processing can all contribute. That complexity helps explain the appeal of a cell therapy designed to interact with multiple local signals, but it also raises the burden of showing exactly what the cells do, how long they remain active, and whether their effect is safe and reproducible. SereNeuro has not published human clinical efficacy data for SN101, and the planned FDA meeting is not an authorization to begin a trial. The next meaningful evidence will come from the IND-enabling package, the regulator's response, and any future clinical protocol. The round amount, named investors, valuation, and total funding also remain outside the public record. That restraint does not diminish the scientific story. It locates the company accurately inside it. SereNeuro has a memorable mechanism, a verified preclinical program, a team spanning Johns Hopkins science and biotech development, and enough new capital to ask the harder questions. The work now is to manufacture the same cells repeatedly, define the safety case, and learn whether the observation that created SN101 can survive the discipline required to reach patients.

SereNeuro Therapeutics closes oversubscribed pre-seed financing to advance non-opioid pain pipeline. Oct 05, 2026, 07:00 ET Lead program SN101, a first-in-class non-opioid iPSC-derived therapy for chronic joint pain, moves toward IND-enabling studies BALTIMORE and PHOENIX, Oct. 5, 2026 /PRNewswire/ - SereNeuro Therapeutics, a preclinical-stage biotechnology company developing non-opioid therapies for pain, today announced the close of its oversubscribed pre-seed financing. The round advances the company's lead program, SN101, toward Investigational New Drug (IND)-enabling activities and supports its second program, SN102. The syndicate included two Maryland-based venture firms and a physician investor. Qualifying investors structured their investments through Maryland's Biotechnology Investment Incentive Tax Credit at the enhanced refundable rate available to companies located in a federal Opportunity Zone, which includes SereNeuro's East Baltimore site. "Non-opioid pain therapeutics have become one of the most active corners of biotech this year, with an IPO, nine-figure financings, and pharma licensing deals, nearly all of it chasing one family of sodium channels for symptom relief," said Daniel Saragnese, MBA, CEO and co-founder of SereNeuro Therapeutics. "SereNeuro brings a different biology to the same problem. SN101 is made of living human sensory neurons that carry the full pain-channel identity of a native human dorsal root ganglion, or DRG, neuron: Nav1.7, Nav1.8, and Nav1.9, which most stem-cell-derived neurons lack. SN101 cells are designed to relieve pain and preserve the joint. This capital, with the non-dilutive funding we continue to secure, carries SN101 toward the manufacturing and preclinical studies an IND requires." SN101 is an off-the-shelf, non-opioid therapy made of purified human pain-sensing neurons derived from induced pluripotent stem cells (iPSCs). Delivered by a single injection into the affected joint, it is designed to relieve chronic joint pain while preserving joint structure, and it has demonstrated preclinical proof of concept. The technology was developed by co-founders Xinzhong Dong, Ph.D., Gabsang Lee, D.V.M., Ph.D., and Zhuolun (Poppy) Wang, Ph.D. "Gabsang and I began this collaboration to build a human iPSC-derived model of peripheral pain-sensing neurons, pure and specific enough to control for neuron subtype, so we could discover new non-opioid pain drug targets. It was never meant to be a drug. We were testing the cells' function to validate the model. A joint pain model was available, and when we put the cells into the joint, we saw a therapeutic effect we had not set out to find. That observation became SN101," said Xinzhong Dong, Ph.D., co-founder and scientific advisor. SN102, the company's second program, is a gene therapy for trigeminal neuralgia and other neuropathic pain. "Our goal with SN102 is a single treatment that turns down pain signaling in trigeminal neuralgia and other neuropathic pain, from the neurons themselves, without opioids and without numbing everything else," said Zhuolun (Poppy) Wang, Ph.D., co-founder and scientific advisor. In September 2026, after the financing closed, SereNeuro received its first NIH Small Business Innovation Research (SBIR) award, supporting SN102 through the Helping to End Addiction Long-term(R) Initiative, or NIH HEAL Initiative, an NIH-wide effort to speed scientific solutions to the opioid crisis, including non-addictive treatments for pain. SereNeuro's pipeline is built for that purpose. The company was also selected by the Alliance for Regenerative Medicine to present an Innovation Spotlight at the 2026 Cell & Gene Meeting on the Mesa, taking place today: * Date: Monday, October 5, 2026 * Time: 2:30 p.m. MST (5:30 p.m. EDT) * Location: Frank Lloyd Wright Ballroom G, Arizona Biltmore, Phoenix About SereNeuro Therapeutics SereNeuro Therapeutics is a preclinical-stage biotechnology company developing first-in-class non-opioid therapies for pain, including iPSC-derived neuron therapies and gene therapies, led by SN101. For more information, visit www.sereneuro.com. SereNeuro's SN102 program is supported by the National Institute of Dental and Craniofacial Research of the National Institutes of Health under Award Number R43DE035747. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Media Contact Daniel Saragnese, MBA, CEO and co-founder [email protected] +1 410-205-9387 SOURCE SereNeuro Therapeutics, Inc.